TrialThe Journal of dermatology2025

Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study.

Yukari Okubo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.